Charles Schwab
IMNM icon

Charles Schwab’s Immunome IMNM Stock Holding History

Charles Schwab’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
886,193
+34,404
+4% +$736K ﹤0.01% 1862
2026
Q1 		$18.6M Buy
851,789
+11,100
+1% +$247K ﹤0.01% 1783
2025
Q4 		$18.1M Buy
840,689
+177,077
+27% +$3.11M ﹤0.01% 1814
2025
Q3 		$7.77M Buy
663,612
+23,363
+4% +$232K ﹤0.01% 2229
2025
Q2 		$5.95M Buy
640,249
+25,862
+4% +$212K ﹤0.01% 2257
2025
Q1 		$4.13M Buy
614,387
+157,135
+34% +$1.51M ﹤0.01% 2347
2024
Q4 		$4.86M Buy
457,252
+14,775
+3% +$179K ﹤0.01% 2347
2024
Q3 		$6.47M Buy
442,477
+302,916
+217% +$4.3M ﹤0.01% 2242
2024
Q2 		$1.69M Buy
139,561
+121,585
+676% +$1.9M ﹤0.01% 2756
2024
Q1 		$444K Buy
+17,976
New +$365K ﹤0.01% 3074

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Charles Schwab's IMNM Position: Q2 2026 in Review

Charles Schwab increased its Immunome (IMNM) stake by 4% in Q2 2026, buying an estimated $736K and bringing the position to 886,193 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

Charles Schwab first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Charles Schwab held 886,193 shares of Immunome worth $18.8M as of Q2 2026.
  • Charles Schwab bought 34,404 Immunome shares in Q2 2026, an estimated $736K.
  • Immunome made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1862 holding.
  • Charles Schwab first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.